VEXT SCIENCE INC - VEXTF STOCK NEWS

Vext Science (VEXTF) has secured a provisional license for its fifth cannabis dispensary in Portsmouth, Ohio, strengthening its retail presence in this -license market. The dispensary is expected to begin operations in Q2 or Q3 2025, pending regulatory approvals. The company acquired the associated real property through a $350,000 mortgage at 10% annual interest over 15 years.

Vext currently operates a Tier I cultivation facility, a manufacturing facility, and two retail dispensaries in Jackson and Columbus. The company aims to reach Ohio's state license cap of eight dispensaries through previously announced acquisitions and additional 10(B) licenses. The Portsmouth location, situated along the Ohio River, represents a strategic expansion in southern Ohio.

Vext Science (CSE: VEXT) (OTCQX: VEXTF), a U.S.-based cannabis operator with operations in Arizona and Ohio, has expanded its engagement with Zuanic & Associates through a Revised Services Agreement. Under the new agreement, Zuanic will provide advisory, research, and investor relations services to Vext for an initial twelve-month term starting October 1, 2024. The services will be provided for a monthly cash fee not exceeding US$7,000. Zuanic, an arm's length financial consulting and research advisory firm based in New Jersey, will deliver these services through various mediums and platforms.

Vext Science (CSE: VEXT, OTCQX: VEXTF), a U.S.-based cannabis operator with operations in Arizona and Ohio, has distributed Meeting Materials for its upcoming Annual General Meeting scheduled for December 13, 2024. The materials include the Management Information Circular, Notice of Meeting, and proxy form. Due to the Canada Post strike, shareholders can access electronic copies through the company's website, SEDAR+ profile, or by email request. Registered shareholders must submit proxy forms 48 hours before the meeting, excluding weekends and holidays.

Vext Science reported Q3 2024 financial results with revenue of $9.0 million and Adjusted EBITDA of $2.9 million. The company saw a 14.2% sequential increase in consolidated retail sales, driven by adult-use sales growth in Ohio and market share gains in Arizona. Q3 performance showed significant improvement with Adjusted EBITDA margin reaching 32.0%, up from 12.9% in Q2 2024. The company is positioned to expand its Ohio footprint to reach the state dispensary license cap of 8, with new locations planned to open throughout 2025 and early 2026.

Vext Science (CSE: VEXT) (OTCQX: VEXTF), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, has scheduled its Q3 2024 financial results release for November 21, 2024, before market open. The company will host a conference call and webcast on the same day at 8:00 a.m. ET. A replay of the conference call will be available until December 5, 2024, and the webcast will be accessible through Vext's investor website.

Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, has entered into a Services Agreement with PartnerCap Securities, The agreement, effective September 23, 2024, engages PartnerCap to provide services including Investor Relations Activities such as research and publication services.

The initial term of the agreement is six months, with automatic three-month renewals thereafter. Vext will pay PartnerCap a cash fee of US$18,000 for the initial term and US$9,000 for each subsequent three-month renewal. Additional fees may apply for services beyond Investor Relations Activities.

PartnerCap is a FINRA registered brokerage firm based in Bluffton, South Carolina, and operates at arm's length from Vext.

Vext Science (CSE: VEXT) (OTCQX: VEXTF) reported Q2 2024 financial results with revenue of $8.4 million and Adjusted EBITDA of $1.1 million. The company is well-positioned in Ohio's newly launched adult-use cannabis market, with a large footprint including a Tier 1 cultivation facility, manufacturing facility, and two retail dispensaries. Vext expects to reach the state dispensary license cap in 2024.

Key financial highlights:

• Q2 2024 revenue: $8,426,928
• Q2 2024 EBITDA: $171,309
• Q2 2024 Adjusted EBITDA margin: 12.9%

CEO Eric Offenberger noted the challenges in the consumer sector but expressed optimism about Ohio's adult-use market potential. The company is focusing on transitioning Ohio dispensaries to serve both medical and adult-use markets, enhancing Arizona operations, and exploring growth opportunities.

Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, has announced plans to release its financial results for the second quarter ended June 30, 2024, before market open on August 20, 2024. The company will host a conference call and webcast on the same day at 08:00 a.m. ET.

Conference call details include:

• Date: August 20, 2024
• Time: 8:00 am E.T.
• Participant Dial-in: +1-647-484-8814 or 1-844-763-8274
• Conference ID: 10191819

A replay of the call and webcast will be available on Vext's investor website after the event.

Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) has announced the commencement of adult-use cannabis sales in Ohio on August 6, 2024. The company has secured Certificates of Operation for dual licensing of its cultivation and manufacturing facility as well as its operated dispensaries in Jackson and Columbus. Vext's current footprint in Ohio includes a 25,000 square feet Tier 1 cultivation facility (expandable to 50,000 square feet), a manufacturing facility, and two operating dispensaries. The company has agreements for two additional dispensaries and is entitled to receive three more adult-use licenses as a Tier 1 Cultivator, potentially bringing its total retail footprint in Ohio to seven locations.